Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039
Wolfgang Miesbach /LinkedIn
Sep 24, 2025, 11:06

Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:

“Promising results in new subcutaneous von Willebrand disease treatment presented at BIC 2025!

Carolyn Miller presented Phase I results for VGA039:

This monoclonal antibody targets Protein S to restore balance in blood clotting by inhibiting both tissue factor pathway inhibitor α (TFPIα) and activated protein C (aPC), enhancing thrombin generation during both initiation and propagation phases of coagulation.

The VIVID 2 study enrolled 10 VWD patients (ages 21-52) with diverse VWD subtypes, including those with mild hemophilia A. Results showed increased thrombin generation lasting 4+ weeks without dose-limiting toxicities:

Safe and well-tolerated across all VWD types (1, 2A, 2M, 2N, 3)

  • Single subcutaneous injection maintained therapeutic concentrations for ~4 weeks
  • Significant bleed reduction: 75-88% reduction in annualized bleeding rates in high-bleed patients
  • Universal approach: Works across all VWD types by targeting Protein S

Unlike current VWD treatments requiring multiple weekly IV infusions, VGA039 may offer convenient subcutaneous dosing with sustained multi-week protection.”

Subcutaneous

More recent insights on Hemostasis Today.

activated protein C (aPC) BIC 2025 bleeding disorders Carolyn Miller Health Hematology Hemostasis Hemostasis Today Medicine Subcutaneous Thrombin tissue factor pathway inhibitor α (TFPIα) VGA039 VIVID 2 Von Willebrand Disease Wolfgang Miesbach
NewsFeed